Epsilogen and Lonza have successfully completed the manufacturing of a potential cancer treatment. The complex process, which took less than ten months, was carried out...
14.06.2017
- US pharmaceutical giant Merck has announced it is suspending new enrollments in two phase 3 multiple myeloma studies with its blockbuster immunotherapy drug Keytruda (pembrolizumab...
01.06.2017
- UK biotech Bicycle Therapeutics has raised £40 million from a Series B financing round to advance the development of multiple candidate drugs to treat cancers with a high unmet...
12.10.2016
- The UK’s Crescendo Biologics is collaborating with Japanese drugmaker Takeda Pharmaceutical Company in a deal worth $790 million. The partners have announced a global, strategic...
06.10.2016
- US biotechnology group Genentech has agreed with Hanmi Pharmaceutical to buy the exclusive global rights to the South Korean company’s experimental cancer drug HM95573. The...
07.03.2016
- French pharmaceutical company Ipsen is paying up to $855 million for the rights to Exelixis’ cancer drug Cabozantinib. Under the deal, Exelixis gains exclusive commercialization...
